Idorsia Ltd
SIX:IDIA
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.6325
2.86
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CHF.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Idorsia Ltd
Idorsia Ltd
Selling, General & Administrative
Idorsia Ltd
Selling, General & Administrative Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Selling, General & Administrative | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Idorsia Ltd
SIX:IDIA
|
Selling, General & Administrative
-CHf386m
|
CAGR 3-Years
-59%
|
CAGR 5-Years
-45%
|
CAGR 10-Years
N/A
|
|
|
AC Immune SA
NASDAQ:ACIU
|
Selling, General & Administrative
-CHf13.5m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Selling, General & Administrative
-$201.6m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
N/A
|
|
|
Molecular Partners AG
SIX:MOLN
|
Selling, General & Administrative
-CHf22.6m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Selling, General & Administrative
-CHf32.6m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-4%
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Selling, General & Administrative
-CHf44.2m
|
CAGR 3-Years
-57%
|
CAGR 5-Years
-42%
|
CAGR 10-Years
N/A
|
|
Idorsia Ltd
Glance View
Idorsia Ltd. operates as a biopharmaceutical firm which focuses on discovery, development and commercialization of innovative medicines for unmet medical needs. The company is headquartered in Allschwil, Basel-Landschaft. The company went IPO on 2017-06-16. The firm will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The firm's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.
See Also
What is Idorsia Ltd's Selling, General & Administrative?
Selling, General & Administrative
-386m
CHF
Based on the financial report for Dec 31, 2023, Idorsia Ltd's Selling, General & Administrative amounts to -386m CHF.
What is Idorsia Ltd's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 5Y
-45%
Over the last year, the Selling, General & Administrative growth was 23%. The average annual Selling, General & Administrative growth rates for Idorsia Ltd have been -59% over the past three years , -45% over the past five years .
You don't have any saved screeners yet